What Causes Low Estrogen?

The Estrogen Production Pathway and Where It Breaks Down

Estradiol (E2), the most biologically active estrogen, is synthesized primarily in ovarian granulosa cells through aromatization of androgens. The hypothalamic-pituitary-ovarian (HPO) axis controls this process: gonadotropin-releasing hormone (GnRH) pulses from the hypothalamus stimulate FSH and LH release from the anterior pituitary, which then drive follicular development and steroidogenesis in the ovary [1].

Any disruption along this axis produces hypoestrogenism. The clinical classification divides causes into three tiers: hypothalamic-pituitary (central), ovarian (primary), and iatrogenic or pharmacologic. A 2020 Endocrine Society review noted that distinguishing central from peripheral causes requires measuring FSH alongside estradiol. Elevated FSH (above 25 IU/L on two separate draws) with low E2 points to ovarian failure, while low or normal FSH with low E2 suggests hypothalamic or pituitary suppression [2].

Peripheral conversion in adipose tissue via aromatase also contributes to circulating estrogen, particularly after menopause. Women with very low body fat lose this secondary source entirely.

Natural Menopause: The Most Common Cause

The single most frequent reason for low estrogen is natural ovarian aging. Women are born with approximately 1-2 million oocytes; by menarche this drops to around 300,000-400,000. The decline accelerates after age 37, and when the follicular pool falls below roughly 1,000 remaining follicles, menopause ensues [3].

The Study of Women's Health Across the Nation (SWAN), which followed 3,302 women longitudinally, documented that estradiol drops by approximately 50% during the late menopausal transition and stabilizes at postmenopausal levels of 10-20 pg/mL within two years of the final menstrual period [4]. The median age at natural menopause in the United States is 51.4 years, but the perimenopausal decline begins 4-8 years earlier.

Genetic factors explain roughly 50-85% of the variance in menopausal timing. Specific loci identified in genome-wide association studies include MCM8, BRSK1, and variants near the FSHB gene [5]. Ethnicity also matters: SWAN data showed that Black and Hispanic women reached menopause slightly earlier than white women on average.

Premature Ovarian Insufficiency (POI)

POI, defined as loss of ovarian function before age 40, affects approximately 1% of women under 40 and 0.1% under 30 [6]. FSH levels exceed 25 IU/L on two measurements taken at least four weeks apart, and estradiol falls below the premenopausal range.

The etiology breaks down as follows:

Genetic causes account for 20-25% of cases. Turner syndrome (45,X) and FMR1 premutations (55-200 CGG repeats) are the most common identifiable genetic contributors. The European Society of Human Reproduction and Embryology (ESHRE) 2024 guideline recommends karyotyping and FMR1 testing for all women diagnosed with POI before age 40 [7].

Autoimmune causes represent 4-30% depending on the population studied. Autoimmune oophoritis frequently co-occurs with Addison disease, Hashimoto thyroiditis, or type 1 diabetes. The presence of adrenal antibodies (21-hydroxylase antibodies) carries a 50% risk of progressing to adrenal insufficiency [8].

Idiopathic remains the largest category. No identifiable cause is found in 50-70% of POI cases despite thorough evaluation.

Dr. Nanette Santoro, professor of obstetrics and gynecology at the University of Colorado, has stated: "POI is not simply early menopause. It is a distinct diagnosis with distinct health consequences, particularly for bone and cardiovascular risk, that demand proactive estrogen replacement until at least the natural age of menopause" [7].

Hypothalamic Amenorrhea and Functional Suppression

Functional hypothalamic amenorrhea (FHA) represents the second major category of low estrogen in premenopausal women. GnRH pulse frequency slows or ceases entirely in response to energy deficit, psychological stress, or excessive exercise. The Endocrine Society Clinical Practice Guideline (2017) defines FHA as amenorrhea of six months or more duration due to functional suppression of the HPO axis, after exclusion of organic pathology [9].

Three overlapping triggers drive FHA:

Energy deficit. Even modest caloric restriction (as little as a 20-30% deficit sustained over weeks) suppresses LH pulsatility. The hormone leptin serves as the metabolic signal: when adipose stores fall, leptin drops, and kisspeptin neurons in the arcuate nucleus reduce GnRH stimulation. A landmark study by Loucks et al. demonstrated that energy availability below 30 kcal/kg lean body mass/day reliably suppresses reproductive hormones [10].

Excessive exercise. The Female Athlete Triad (now broadened to Relative Energy Deficiency in Sport, or RED-S) combines low energy availability, menstrual dysfunction, and low bone mineral density. Prevalence of amenorrhea reaches 44% in ballet dancers and 26% in competitive runners [11].

Psychological stress. Cortisol-releasing hormone directly inhibits GnRH neurons. Acute psychological trauma, chronic anxiety, and depression can each independently suppress the reproductive axis, though energy deficit remains the stronger predictor.

Estradiol levels in FHA typically range from 20-40 pg/mL. This is sufficient to impair bone accrual but often insufficient to cause the severe vasomotor symptoms seen in menopause. The bone consequences are serious: women with FHA lose 2-6% of spine BMD per year of amenorrhea [9].

Surgical and Radiation-Induced Menopause

Bilateral oophorectomy causes an abrupt, complete cessation of ovarian estrogen production. Unlike natural menopause, where residual ovarian stroma continues producing small amounts of androgens (which undergo peripheral aromatization), surgical menopause eliminates the ovarian contribution entirely. Estradiol falls to undetectable levels within 24-48 hours of surgery.

The Nurses' Health Study (N=29,380 with bilateral oophorectomy) showed that women undergoing oophorectomy before age 45 without estrogen therapy had a 67% increased risk of coronary heart disease and significantly accelerated bone loss compared to age-matched women who retained their ovaries [12].

Pelvic radiation also damages the ovarian follicular pool in a dose-dependent manner. Doses exceeding 6 Gy to the ovaries carry a greater than 97% risk of permanent ovarian failure in women over 40. Younger women tolerate higher doses because of their larger follicular reserve, but doses above 20 Gy cause permanent failure regardless of age [13].

Chemotherapy-Related Ovarian Toxicity

Alkylating agents (cyclophosphamide, busulfan, melphalan) are the most gonadotoxic class. Cyclophosphamide at cumulative doses above 7.5 g/m² causes permanent amenorrhea in more than 70% of women over 30 [14]. The risk equation depends on age at treatment, cumulative dose, and specific agent.

The American Society of Clinical Oncology (ASCO) recommends discussing fertility preservation and the risk of premature menopause before initiating gonadotoxic chemotherapy. GnRH agonist co-treatment during chemotherapy may provide partial ovarian protection. A meta-analysis of 12 randomized trials (N=1,231) found that GnRH agonist co-administration reduced the rate of premature ovarian failure from 30.9% to 14.1% [15].

Newer targeted therapies and immunotherapy agents generally have lower ovarian toxicity, though long-term data remain limited.

Medications That Suppress Estrogen

Several drug classes intentionally or incidentally lower estrogen:

Aromatase inhibitors (anastrozole, letrozole, exemestane) block the conversion of androgens to estrogen in peripheral tissues. Used in estrogen-receptor-positive breast cancer, they reduce serum estradiol by 85-95% in postmenopausal women [16]. Side effects directly attributable to profound hypoestrogenism include arthralgia (occurring in up to 50% of patients), accelerated bone loss (2-3% per year at the lumbar spine), and vaginal dryness.

GnRH agonists (leuprolide, goserelin) initially stimulate then suppress the HPO axis, producing a medical menopause within 2-4 weeks. Prescribed for endometriosis, uterine fibroids, and breast cancer, they reduce estradiol to postmenopausal levels (typically <20 pg/mL). Add-back therapy with low-dose estrogen/progestogen mitigates bone loss and vasomotor symptoms during extended use [17].

GnRH antagonists (elagolix, relugolix) offer dose-dependent suppression without the initial flare. Elagolix at 200 mg twice daily reduces estradiol by approximately 95%, while 150 mg once daily achieves partial suppression (around 50% reduction), preserving some estrogenic activity to limit bone loss [18].

Medroxyprogesterone acetate (DMPA) for contraception suppresses ovarian steroidogenesis sufficiently to reduce estradiol levels by 30-50% in some users. A Cochrane review noted measurable reductions in bone mineral density during DMPA use, though most is recovered after discontinuation [19].

Systemic and Metabolic Conditions

Hyperprolactinemia. Elevated prolactin (from pituitary adenomas or medications like antipsychotics) suppresses GnRH pulsatility, leading to anovulation and hypoestrogenism. Serum prolactin above 100 ng/mL is more likely to represent a prolactinoma than medication effect [20].

Thyroid dysfunction. Severe hypothyroidism elevates TRH, which stimulates prolactin secretion and can disrupt the menstrual cycle. Hyperthyroidism increases sex hormone-binding globulin (SHBG), reducing bioavailable estradiol.

Chronic kidney disease. Uremia disrupts the HPO axis at multiple levels. Women on hemodialysis have significantly lower estradiol levels and high rates of amenorrhea.

Eating disorders. Anorexia nervosa produces the most severe form of FHA. Estradiol levels frequently fall below 20 pg/mL. The bone consequences are devastating: women with anorexia have fracture rates seven times higher than age-matched controls [21].

Galactosemia. This rare inborn error of metabolism causes toxic accumulation of galactose-1-phosphate in the ovaries, leading to POI in approximately 80% of affected women.

Lifestyle and Environmental Factors

Smoking. Cigarette smoke contains polycyclic aromatic hydrocarbons that accelerate follicular atresia and induce hepatic estrogen metabolism. A meta-analysis of 11 studies found that current smokers reach menopause 1-2 years earlier than nonsmokers [22].

Extreme exercise without adequate fueling. As discussed in the FHA section, the mechanism is energy deficit rather than exercise per se. An adequately fueled athlete does not develop suppressed estrogen.

Endocrine-disrupting chemicals. Bisphenol A, phthalates, and certain pesticides may interfere with ovarian steroidogenesis or accelerate follicular depletion. Epidemiologic evidence from NHANES data links higher urinary phthalate metabolites with earlier menopause by 1.9-3.8 years [23]. The clinical significance in individual patients remains difficult to quantify.

Clinical Consequences of Sustained Hypoestrogenism

The downstream effects of chronically low estrogen span multiple organ systems. Bone mineral density declines at 1-3% per year in the early postmenopausal period; untreated POI patients lose significantly more. The WHI Observational Study documented that each 5-year earlier onset of menopause increased hip fracture risk by 8% [24].

Cardiovascular risk rises measurably. Estrogen promotes endothelial nitric oxide synthesis, favorable lipid profiles (higher HDL, lower LDL), and arterial compliance. The Framingham Heart Study showed a doubling of cardiovascular event rates in the decade following menopause [25].

Genitourinary syndrome of menopause (GSM) affects up to 84% of postmenopausal women, with vaginal dryness, dyspareunia, and recurrent urinary tract infections directly attributable to urogenital atrophy from estrogen deficiency.

Cognitive effects remain under active investigation. The KEEPS (Kronos Early Estrogen Prevention Study) trial and observational data suggest that the timing of estrogen loss relative to cognitive aging may matter more than absolute levels.

Diagnostic Approach

The 2022 NAMS (North American Menopause Society) position statement recommends the following evaluation when low estrogen is suspected in a premenopausal woman: serum estradiol, FSH, LH, prolactin, TSH, and a pregnancy test [26]. If FSH is elevated on two separate draws four weeks apart and the patient is under 40, the diagnosis is POI and warrants karyotype plus FMR1 premutation testing.

For hypothalamic amenorrhea, the Endocrine Society recommends excluding organic causes (MRI to rule out pituitary lesion) before attributing the suppression to functional causes [9].

Postmenopausal women generally do not require laboratory confirmation. Twelve consecutive months of amenorrhea after age 45 is clinically diagnostic. However, serum estradiol measurement becomes relevant when initiating or adjusting hormone therapy to confirm absorption and guide dosing.

The 2024 Endocrine Society guideline on POI states: "All women with POI should be offered hormone replacement therapy until at least the average age of natural menopause (51 years) to mitigate cardiovascular, skeletal, and neurocognitive risks, unless a specific contraindication exists" [7].